Grinterol (Ursodeoxycholic Acid)

Grinterol is prescribed for several liver‑related conditions where bile composition or flow is impaired. It is used under medical supervision to address specific therapeutic goals.

• Primary biliary cholangitis (PBC) to improve liver function and delay disease progression.
• Primary sclerosing cholangitis (PSC) as an adjunctive therapy.
• Dissolution of cholesterol gallstones in patients unsuitable for surgery.
• Supportive treatment in other cholestatic liver disorders.
• Off‑label use may be considered in specialized clinical settings.

Side effects of Grinterol vary in frequency and severity. Patients should be aware of both common and serious reactions.

Common

• Mild gastrointestinal upset such as nausea or abdominal discomfort.
• Diarrhea or loose stools.
• Headache.
• Fatigue.
• Mild elevation of liver enzymes.

Serious

• Severe liver injury or hepatitis.
• Pancreatitis.
• Allergic reactions including rash, itching, or swelling.
• Jaundice worsening.
• Unexplained fever or chills.

Before starting Grinterol, certain precautions should be considered to ensure safe use.

• Liver function should be assessed and monitored regularly during therapy.
• Use with caution in patients with severe hepatic impairment.
• Renal function assessment is recommended for those with kidney disease.
• Pregnancy and breastfeeding status should be discussed with a healthcare professional.
• Pediatric use is not well established and requires specialist guidance.
• Discontinue if signs of serious liver injury appear.
• Inform the prescriber of any history of allergic reactions to bile acids.

Grinterol can interact with other medicines, affecting its absorption or potency. Awareness of these interactions helps maintain therapeutic effectiveness.

Avoid

• Bile acid sequestrants such as cholestyramine, colestipol, or colesevelam, which can reduce absorption of ursodeoxycholic acid.
• High‑dose vitamin supplements that may interfere with bile metabolism.

Use with caution

• Anticoagulants like warfarin, as ursodeoxycholic acid may alter INR values.
• Immunosuppressants (e.g., cyclosporine) due to potential hepatic effects.
• Oral contraceptives, which could affect hormone metabolism.
• Other hepatotoxic drugs, requiring closer liver monitoring.
• Statins, as combined use may increase risk of liver enzyme elevation.